@article{ab7e7db26356482ab4b90a9ee23ee4bc,
title = "Food Insecurity in the Food Allergic Population: A Work Group Report of the AAAAI Adverse Reactions to Foods Committee",
abstract = "Food allergies affect 32 million Americans. Restricted diets due to food allergies can be difficult to maintain especially when the household is food insecure. Food insecurity is defined as the inability to acquire food for household members due to insufficient money or resources for food. The COVID-19 pandemic has caused many people to face food insecurity for the first time with Latinx, Native American, and Black communities disproportionately affected. Because of the increase in food insecurity, this work group developed a survey regarding food insecurity screening. This survey was sent out to a random sample of American Academy of Allergy Asthma & Immunology members to assess food insecurity knowledge and practices. The majority of survey participants did not routinely screen their patients for food insecurity. The biggest barrier identified to screening was lack of knowledge of how to perform a screen and resources available when a patient screened positive. This work group report provides guidance on how to implement and perform a food insecurity screen, including federal resources and assistance programs.",
keywords = "COVID-19 pandemic, Food access, Food allergy, Food assistance programs, Food insecurity, Food security, Health disparities, Nutrition, Social determinants of health",
author = "Jodi Shroba and Rajeshree Das and Lucy Bilaver and Eileen Vincent and Emily Brown and Brooke Polk and Ashley Ramos and Russell, {Anne F.} and Bird, {J. Andrew} and Ciaccio, {Christina E.} and Lanser, {Bruce J.} and Kim Mudd and Amika Sood and Vickery, {Brian P.} and Ruchi Gupta",
note = "Funding Information: Conflicts of Interest: J. Shroba reports speaker's fees for Aimmune Therapeutics outside the submitted work. L. Bilaver reports research support from the National Institutes of Health (NIH), Food Allergy Research Education (FARE), Rho Inc, Thermo Fisher Scientific, Genentech, Before Brands, and the National Confectioners Association (NCA). E. Brown reports consulting work for Alladapt. J. A. Bird reports grant support for contracted research from NIH-NIAID, Genentech, FARE, Aimmune Therapeutics, DBV Technologies, and Astellas; personal fees from Pharm-Olam International Ltd for DSMB service; consulting compensation from Pfizer Pharmaceuticals, Prota Therapeutics, Allergy Therapeutics, Ltd, AllerGenis, Novartis, Before Brands, FARE, Aimmune Therapeutics, and DBV Technologies outside the submitted work; speaker's fees from Aimmune Therapeutics and DBV Technologies outside the submitted work. C. E. Ciaccio reports funding support from Paul and Mary Yovovich. B. J. Lanser reports grant support for contracted research from NIH-NIAID, Genentech, Aimmune Therapeutics, DBV Technologies, and Regeneron; consulting compensation from AllerGenis, Genentech, Aimmune Therapeutics, and DBV Technologies outside the submitted work; speaker's fees from Aimmune Therapeutics outside the submitted work. A. Sood reports research support from NIH-NIAID. B. P. Vickery reports grants and personal fees from Aimmune, personal fees from AllerGenis, personal fees from Aravax, grants from DBV, grants and personal fees from FARE, grants from Genentech, grants from NIH-NIAID, personal fees from Reacta Biosciences, and grants and personal fees from Regeneron, all outside the submitted work. R. Gupta reports research support from the NIH (R21 ID # AI135705, R01 ID # AI130348, U01 ID # AI138907), FARE, Rho Inc, Melchiorre Family Foundation, Sunshine Charitable Foundation, Walder Foundation, UnitedHealth Group, Thermo Fisher Scientific, Genentech, and the National Confectioners Association (NCA); serves as a medical consultant/advisor for Aimmune Therapeutics, Before Brands, AllerGenis LLC, Kal{\'e}o Inc, Novartis, Genentech, DBV Technologies, and FARE; is employed by Ann & Robert H. Lurie Children's Hospital of Chicago; and is professor of pediatrics and medicine at Northwestern University Feinberg School of Medicine. The rest of the authors declare that they have no relevant conflicts of interest. Funding Information: Conflicts of Interest: J. Shroba reports speaker's fees for Aimmune Therapeutics outside the submitted work. L. Bilaver reports research support from the National Institutes of Health (NIH), Food Allergy Research Education (FARE), Rho Inc, Thermo Fisher Scientific, Genentech, Before Brands, and the National Confectioners Association (NCA). E. Brown reports consulting work for Alladapt. J. A. Bird reports grant support for contracted research from NIH-NIAID, Genentech, FARE, Aimmune Therapeutics, DBV Technologies, and Astellas; personal fees from Pharm-Olam International Ltd for DSMB service; consulting compensation from Pfizer Pharmaceuticals, Prota Therapeutics, Allergy Therapeutics, Ltd, AllerGenis, Novartis, Before Brands, FARE, Aimmune Therapeutics, and DBV Technologies outside the submitted work; speaker{\textquoteright}s fees from Aimmune Therapeutics and DBV Technologies outside the submitted work. C. E. Ciaccio reports funding support from Paul and Mary Yovovich. B. J. Lanser reports grant support for contracted research from NIH-NIAID, Genentech, Aimmune Therapeutics, DBV Technologies, and Regeneron; consulting compensation from AllerGenis, Genentech, Aimmune Therapeutics, and DBV Technologies outside the submitted work; speaker{\textquoteright}s fees from Aimmune Therapeutics outside the submitted work. A. Sood reports research support from NIH-NIAID. B. P. Vickery reports grants and personal fees from Aimmune, personal fees from AllerGenis, personal fees from Aravax, grants from DBV, grants and personal fees from FARE, grants from Genentech, grants from NIH-NIAID, personal fees from Reacta Biosciences, and grants and personal fees from Regeneron, all outside the submitted work. R. Gupta reports research support from the NIH (R21 ID # AI135705, R01 ID # AI130348, U01 ID # AI138907), FARE, Rho Inc, Melchiorre Family Foundation, Sunshine Charitable Foundation, Walder Foundation, UnitedHealth Group, Thermo Fisher Scientific , Genentech, and the National Confectioners Association (NCA); serves as a medical consultant/advisor for Aimmune Therapeutics, Before Brands, AllerGenis LLC, Kal{\'e}o Inc, Novartis, Genentech, DBV Technologies, and FARE; is employed by Ann & Robert H. Lurie Children{\textquoteright}s Hospital of Chicago; and is professor of pediatrics and medicine at Northwestern University Feinberg School of Medicine. The rest of the authors declare that they have no relevant conflicts of interest. Publisher Copyright: {\textcopyright} 2021 American Academy of Allergy, Asthma & Immunology",
year = "2022",
month = jan,
doi = "10.1016/j.jaip.2021.10.058",
language = "English",
volume = "10",
pages = "81--90",
journal = "Journal of Allergy and Clinical Immunology: In Practice",
issn = "2213-2198",
number = "1",
}